Lv1
20 积分 2024-10-03 加入
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
3天前
已完结
Prolgolimab with Chemotherapy as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer
3天前
已完结
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG-3041/ENGOT-EN10): Objective response rate and duration of response by mismatch repair status
3天前
已关闭
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
4天前
已完结
Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis
23天前
已完结
Age-related decline in CD8+ tissue resident memory T cells compromises antitumor immunity
28天前
已完结
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial
29天前
已完结
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
1个月前
已完结
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
1个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
1个月前
已完结
皖公网安备34019202002308
